Compare ACADIA Pharmaceuticals Inc. (ACAD) vs GameStop Corp. (GME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs GameStop Corp. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.67 (market cap $5.07B), while GameStop Corp. trades at $18.63 (market cap $8.44B). The key difference: GameStop Corp. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, GameStop Corp. nearer its low. Which is the better fit depends on your goals.
| ACAD | GME | |
|---|---|---|
Market Cap | $5.07B | $8.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.41 | $27.69 |
52-Week Low | $20.06 | $18.79 |
Enterprise Value | $4.19B | $4.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
GME trades at $18.57, down 1.2% with bearish technical signals from moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and a significant turnaround to profitability, achieving a 20.45% net income margin in 2025. Recent news highlights strategic shifts including potential partnership discussions with eBay instead of a full acquisition. Cash position strengthened to $4.77 billion following a $3.85 billion net cash inflow in 2025.
The outlook remains mixed with strong profitability improvements offset by bearish technical indicators and cautious analyst sentiment. Investment opportunity exists in the company's operational turnaround and cash-rich balance sheet, while risks include potential shareholder dilution from recent debt conversions and ongoing competitive pressures in the retail gaming sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →
